GlassScriptPhysician profile
Douglas Todd Vick
NPI 1043385123
$1,685.30
in general payments reported to CMS, 2019-2025
31 companies · $204 in 2025
The $204 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $155 · 2022: $20.51 · 2023: $1,228 · 2024: $78.35 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,509.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $342.99 | 2023 | |
| Ucb, INC. | $148.75 | 2023 | Cimzia |
| Forte Bio-Pharma LLC | $126.86 | 2024-2025 | Prolate, Nalocet, Tanlor |
| Janssen Biotech, INC. | $106.22 | 2023 | Simponi Aria, Tremfya, Remicade |
| Novartis Pharmaceuticals Corporation | $88.38 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $81.85 | 2023 | |
| Lilly USA, LLC | $71.36 | 2023 | Taltz |
| Amgen INC. | $68.30 | 2023 | Enbrel, Otezla |
| Collegium Pharmaceutical, INC. | $67.98 | 2025 | Belbuca |
| Janssen Pharmaceuticals, INC | $52.96 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $44.59 | 2023 | Acthar |
| Sandoz INC. | $44.21 | 2023 | |
| Mylan Institutional INC. | $43.83 | 2023 | Hulio |
| Radius Health, INC. | $43.56 | 2021-2023 | Tymlos |
| Takeda Pharmaceuticals U.S.A., INC. | $36.25 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $29.41 | 2023 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.22 | 2023 | Ofev |
| Spr Therapeutics, INC | $25.55 | 2024 | Sprint Pns System |
| Abbott Laboratories | $24.86 | 2024 | Octrode |
| Lundbeck LLC | $23.59 | 2023 | Vyepti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.16 | 2025 | Relistor |
| Alexion Pharmaceuticals, INC. | $22.83 | 2023 | Ultomiris |
| Actelion Pharmaceuticals US, INC. | $20.92 | 2023 | Uptravi, Opsumit |
| Pfizer INC. | $18.68 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $18.64 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $17.64 | 2023 | Ajovy |
| Eisai INC. | $14.30 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.75 | 2021 | |
| Scilex Pharmaceuticals INC. | $13.60 | 2025 | |
| Biodelivery Sciences International, INC. | $12.10 | 2021 | |
| Nevro Corp. | $11.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Vick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.